In July to August 2025, the Charlotte Lozier Institute (CLI) submitted three comments regarding three citizen petitions submitted to the Food and Drug Administration requesting regulatory action on the abortion drug mifepristone. Below, brief summaries and links for each of these comments are provided. CLI Comment on Massachusetts AG et al. Citizen Petition (Submitted 7/24). […]| Lozier Institute
SB 6 allows parents of aborted babies – including fathers – to bring wrongful death suits against abortion pill distributors and empowers Texas’ attorney general to sue on behalf of the unborn.| LifeSite
CLI analysis notes rise in abortions coincides with Planned Parenthood’s growing focus on abortion and the expanded use of abortion drugs. Washington D.C.— A new peer-reviewed article from the Charlotte Lozier Institute (CLI) highlights the factors behind the 20% rise in U.S. abortions from 2017 to 2023, reversing a 30-year decline. The article emphasizes trends […]| Lozier Institute
The decades-long claim, promoted by the abortion lobby, is a faulty comparison not backed by science Washington D.C.—The Charlotte Lozier Institute (CLI) released a new pivotal peer-reviewed article published in the journal BioTech. This article challenges and disproves the baseless claim that “abortion drugs are safer than Tylenol” because it lacks scientific credibility and […]| Lozier Institute